A Study to Evaluate Escalating Doses of ASP1235 (AGS62P1) Given as Monotherapy in Subjects With Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia Clinical Trial

Official title:

A Phase 1 Study Evaluating Safety, Tolerability, and Pharmacokinetics of Escalating Doses of ASP1235 (AGS62P1) Given as Monotherapy in Subjects With Acute Myeloid Leukemia (AML)

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02864290
• Other study ID #: 1235-CL-0101
• Secondary ID: AGS62P1-16-1
• Status: Terminated
• Phase: Phase 1
• Start date: November 10, 2016
• Est. completion date: September 3, 2020

Study information

• Verified date: October 2021
• Source: Astellas Pharma Inc
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the safety and tolerability of ASP1235 (AGS62P1) given at three dosing schedules (Schedule A, every three weeks [Q3W] or Schedule B, every other week of a 4 week cycle [Q2W] or Schedule C once a week for 3 weeks of a 4 week cycle) in subjects with acute myeloid leukemia (AML) and determine the maximum tolerated dose (MTD). In addition, this study will assess the pharmacokinetics (PK), the immunogenicity and the anti-leukemic activity of ASP1235 (AGS62P1).

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 43
• Est. completion date: September 3, 2020
• Est. primary completion date: September 3, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Subject has morphologically documented primary or secondary AML by the World Health Organization (WHO) criteria (2008) which is relapsed or refractory after failing at least 1 regimen and is not a candidate for established salvage treatment regimens. For expansion cohorts, patients are eligible if they have had = 3 prior lines of therapy. Lines of therapy include initial induction (up to 2 cycles) with consolidation/maintenance, if applicable, and subsequent salvage regimens. Consolidation alone and stem cell transplantation are not counted as lines of therapy.

• Subject has an Eastern Cooperative Oncology Group performance score (ECOG) = 2

• Subject has adequate renal function with an estimated creatinine clearance of = 30 mL/min by the Cockcroft-Gault equation adjusted for body weight

• Subject has a total bilirubin = 1.5 x upper limit of normal (ULN), albumin = 2.5 g/d, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) = 2.5 x upper limit of normal (ULN)

• Subjects must be competent to comprehend, provide written informed consent, and date an independent ethics committee/institutional review board/research ethics board (IEC/IRB/REB) approved informed consent form

• A female subject is eligible to participate if she is not pregnant and at least one of the following conditions applies:

• Not a woman of childbearing potential (WOCBP) OR

• WOCBP who agrees to follow the contraceptive guidance throughout the treatment period and for at least 6 months after the final study drug administration.

• Female subject must agree not to breastfeed starting at screening and throughout the study period, and for 6 months after the final study drug administration.

• Female subject must not donate ova starting at screening and throughout the study period, and for 6 months after the final study drug administration.

• A male subject with female partner(s) of child-bearing potential must agree to use contraception during the treatment period and for at least 6 months after the final study drug administration.

• A male subject must not donate sperm during the treatment period and for at least 6 months after the final study drug administration.

• Male subject with a pregnant or breastfeeding partner(s) must agree to remain abstinent or use a condom for the duration of the pregnancy or time partner is breastfeeding throughout the study period and for 6 months after the final study drug administration.

Exclusion Criteria:

• Subject has a diagnosis of acute promyelocytic leukemia (APL)

• Subject has preexisting sensory or motor neuropathy Grade = 2 at baseline

• Subject has received small molecule therapy, radiotherapy, immunotherapy, monoclonal antibodies, investigational drug, or chemotherapy within 14 days before first dose of study drug, with the exception of hydroxyurea

• Subject has any Grade = 2 persistent non-hematological toxicity related to allotransplant

• Subject with Graft vs. Host Disease (GVHD) who is receiving treatment with systemic glucocorticoids > 10 mg/day equivalent of prednisone; however, treatment with low dose glucocorticoids (= 10 mg/day equivalent of prednisone) is permitted

• The use of systemic glucocorticoids in excess of 10 mg/day equivalent of prednisone is permitted provided it is not for the treatment of GVHD (e.g. chronic obstructive pulmonary disease, anti-emetic, infusion reactions). The chronic use of topical, inhaled, and locally injected steroids is permitted

• Subject has known current central nervous system (CNS) disease

• Active angina or Class III or IV Congestive Heart Failure (CHF) (New York Heart Association CHF Functional Classification System) or clinically significant cardiac disease within 12 months of the first dose of study drug, including myocardial infarction, unstable angina, Grade 2 or greater peripheral vascular disease, congestive heart failure, uncontrolled hypertension, or arrhythmias not controlled by medication

• Subject has clinical evidence of Disseminated Intravascular Coagulation

• Subject has known positivity for human immunodeficiency virus

• Subject has known active hepatitis B (positive hepatitis B surface antigen [HBs Ag]) or C infection. For subjects who are negative for HBs Ag, but hepatitis B core antibody (HBc Ab) positive, an HB deoxyribonucleic acid (DNA) test will be performed and if positive, the subject will be excluded. Subjects with positive serology but negative hepatitis C virus (HCV) ribonucleic acid (RNA) test results are eligible.

• Subject has an uncontrolled active infection requiring treatment and grade 3 or higher fever 48 hours before the first dose of study drug. Controlled infections (i.e. 3 negative cultures completing antibiotics and/or stable fungal infection in therapy) are allowed provided the subject has a temperature of < 38.3°C within 48 hours of the first dose of study drug.

• Subject has a known sensitivity to any of the components of the investigational product ASP1235 (AGS62P1):

• ASP1235 (AGS62P1)

• L-Histidine base

• L-Histidine HCl

• a, a -Trehalose Dihydrate

• Polysorbate 20

• Major surgery within 28 days of the first dose of study drug

• Subject is pregnant or lactating

• Subject has a condition or situation which may put the subject at significant risk, may confound the study results, or may interfere significantly with subject's participation in the study

• Subject has any medical, psychiatric, addictive or other disorder which compromises the ability of the subject to give written informed consent and/or to comply with procedures

• Subject has ocular condition such as:

• Active infection or corneal ulcer

• Monocularity

• History of corneal transplantation

• Contact lens dependent (if using contact lens, must be able to switch to glasses during the entire study duration)

• Uncontrolled glaucoma (topical medications allowed)

• Uncontrolled or active ocular problems (e.g., retinopathy, macular edema, active uveitis, macular degeneration) requiring surgery, laser treatment, or intravitreal injections

• Papilledema or other active optic nerve disorder

Related Conditions & MeSH terms

• Acute Myeloid Leukemia
• Leukemia
• Leukemia, Myeloid
• Leukemia, Myeloid, Acute

Intervention

Drug:
• ASP1235
intravenous (IV) infusion

Locations

Country	Name	City	State
Canada	Site CA00010	Toronto	Ontario
United States	Site US00003	Baltimore	Maryland
United States	Site US00007	Boston	Massachusetts
United States	Site US00009	Boston	Massachusetts
United States	Site US00006	Duarte	California
United States	Site US00001	Houston	Texas
United States	Site US00004	New York	New York

Sponsors (1)

Lead Sponsor	Collaborator
Astellas Pharma Global Development, Inc.

Countries where clinical trial is conducted

United States,  Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence and nature of adverse events	AEs will be graded using the National Cancer Institute (NCI) Common Terminology Criteria for AEs (CTCAE) grading scale, version 4.03 (National Institutes of Health, 2010).	up to 30 months
Secondary	Incidence of antidrug antibody (ADA) formation to the fully human monoclonal antibody (AGS62P) and antibody-conjugate (ASP1235 [AGS62P1])		up to 46 months
Secondary	Complete response (CR)		up to 46 months
Secondary	Composite complete remission (CRc) rate		up to 46 months
Secondary	Best response rate		up to 46 months
Secondary	Duration of remission		up to 46 months
Secondary	Duration of response		up to 46 months
Secondary	Morphologic leukemia free state (MLFS) rate		up to 30 months
Secondary	Concentration at the end of infusion (CEOI) of total antibody (TAb) in dose escalation part		up to an average of 30 months
Secondary	Concentration at the end of infusion (CEOI) of antibody drug conjugate (ADC) in dose escalation part		up to an average of 30 months
Secondary	Concentration at the end of infusion (CEOI) of metabolite para-acetyl phenylalanine attached to the microtubule disrupting agent linked to linker 30 (pAF-AGL-0185-30) in dose escalation part		up to an average of 30 months
Secondary	Maximum observed concentration (Cmax) of total antibody (TAb) in dose escalation part		up to an average of 30 months
Secondary	Maximum observed concentration (Cmax) of antibody drug conjugate (ADC) in dose escalation part		up to an average of 30 months
Secondary	Maximum observed concentration (Cmax) of metabolite para-acetyl phenylalanine attached to the microtubule disrupting agent linked to linker 30 (pAF-AGL-0185-30) in dose escalation part		up to an average of 30 months
Secondary	Time to maximum concentration (Tmax) of total antibody (TAb) in dose escalation part		up to an average of 30 months
Secondary	Time to maximum concentration (Tmax) of antibody drug conjugate (ADC) in dose escalation part		up to an average of 30 months
Secondary	Time to maximum concentration (Tmax) of metabolite para-acetyl phenylalanine attached to the microtubule disrupting agent linked to linker 30 (pAF-AGL-0185-30) in dose escalation part		up to an average of 30 months
Secondary	Partial area under the serum concentration-time curve (AUC) of total antibody (TAb) in dose escalation part		up to an average of 30 months
Secondary	Partial area under the serum concentration-time curve (AUC) of antibody drug conjugate (ADC) in dose escalation part		up to an average of 30 months
Secondary	Partial area under the serum concentration-time curve (AUC) of metabolite para-acetyl phenylalanine attached to the microtubule disrupting agent linked to linker 30 (pAF-AGL-0185-30) in dose escalation part		up to an average of 30 months
Secondary	Terminal or apparent terminal half-life (t1/2) of total antibody (TAb) in dose escalation part		up to an average of 30 months
Secondary	Terminal or apparent terminal half-life (t1/2) of antibody drug conjugate (ADC) in dose escalation part		up to an average of 30 months
Secondary	Terminal or apparent terminal half-life (t1/2) of metabolite para-acetyl phenylalanine attached to the microtubule disrupting agent linked to linker 30 (pAF-AGL-0185-30) in dose escalation part		up to an average of 30 months
Secondary	Systemic clearance (CL) of total antibody (TAb) in dose escalation part		up to an average of 30 months
Secondary	Systemic clearance (CL) of antibody drug conjugate (ADC) in dose escalation part		up to an average of 30 months
Secondary	Systemic clearance (CL) of metabolite para-acetyl phenylalanine attached to the microtubule disrupting agent linked to linker 30 (pAF-AGL-0185-30) in dose escalation part		up to an average of 30 months
Secondary	Volume of distribution at steady state (Vss) of total antibody (TAb) in dose escalation part		up to an average of 30 months
Secondary	Volume of distribution at steady state (Vss) of antibody drug conjugate (ADC) in dose escalation part		up to an average of 30 months
Secondary	Volume of distribution at steady state (Vss) of metabolite para-acetyl phenylalanine attached to the microtubule disrupting agent linked to linker 30 (pAF-AGL-0185-30) in dose escalation part		up to an average of 30 months
Secondary	Concentration at the end of infusion (CEOI) of total antibody (TAb) in dose expansion part		up to an average of 30 months
Secondary	Concentration at the end of infusion (CEOI) of antibody drug conjugate (ADC) in dose expansion part		up to an average of 30 months
Secondary	Concentration at the end of infusion (CEOI) of metabolite para-acetyl phenylalanine attached to the microtubule disrupting agent linked to linker 30 (pAF-AGL-0185-30) in dose expansion part		up to an average of 30 months
Secondary	Maximum observed concentration (Cmax) of total antibody (TAb) in dose expansion part		up to an average of 30 months
Secondary	Maximum observed concentration (Cmax) of antibody drug conjugate (ADC) in dose expansion part		up to an average of 30 months
Secondary	Maximum observed concentration (Cmax) of metabolite para-acetyl phenylalanine attached to the microtubule disrupting agent linked to linker 30 (pAF-AGL-0185-30) in dose expansion part		up to an average of 30 months
Secondary	Time to maximum concentration (Tmax) of total antibody (TAb) in dose expansion part		up to an average of 30 months
Secondary	Time to maximum concentration (Tmax) of antibody drug conjugate (ADC) in dose expansion part		up to an average of 30 months
Secondary	Time to maximum concentration (Tmax) of metabolite para-acetyl phenylalanine attached to the microtubule disrupting agent linked to linker 30 (pAF-AGL-0185-30) in dose expansion part		up to an average of 30 months
Secondary	Partial area under the serum concentration-time curve (AUC) of total antibody (TAb) in dose expansion part		up to an average of 30 months
Secondary	Partial area under the serum concentration-time curve (AUC) of antibody drug conjugate (ADC) in dose expansion part		up to an average of 30 months
Secondary	Partial area under the serum concentration-time curve (AUC) of metabolite para-acetyl phenylalanine attached to the microtubule disrupting agent linked to linker 30 (pAF-AGL-0185-30) in dose expansion part		up to an average of 30 months
Secondary	Terminal or apparent terminal half-life (t1/2) of total antibody (TAb) in dose expansion part		up to an average of 30 months
Secondary	Terminal or apparent terminal half-life (t1/2) of antibody drug conjugate (ADC) in dose expansion part		up to an average of 30 months
Secondary	Terminal or apparent terminal half-life (t1/2) of metabolite para-acetyl phenylalanine attached to the microtubule disrupting agent linked to linker 30 (pAF-AGL-0185-30) in dose expansion part		up to an average of 30 months
Secondary	Systemic clearance (CL) of total antibody (TAb) in dose expansion part		up to an average of 30 months
Secondary	Systemic clearance (CL) of antibody drug conjugate (ADC) in dose expansion part		up to an average of 30 months
Secondary	Systemic clearance (CL) of metabolite para-acetyl phenylalanine attached to the microtubule disrupting agent linked to linker 30 (pAF-AGL-0185-30) in dose expansion part		up to an average of 30 months
Secondary	Volume of distribution at steady state (Vss) of total antibody (TAb) in dose expansion part		up to an average of 30 months
Secondary	Volume of distribution at steady state (Vss) of antibody drug conjugate (ADC) in dose expansion part		up to an average of 30 months
Secondary	Volume of distribution at steady state (Vss) of metabolite para-acetyl phenylalanine attached to the microtubule disrupting agent linked to linker 30 (pAF-AGL-0185-30) in dose expansion part		up to an average of 30 months

External Links

•   Link to plain language summary of the study on the Trial Results Summaries website
•   Link to results and other applicable study documents on the Astellas Clinical Trials website